tradingkey.logo

ADMA Biologics Inc

ADMA
View Detailed Chart

15.910USD

-0.250-1.55%
Close 09/19, 16:00ETQuotes delayed by 15 min
3.80BMarket Cap
18.17P/E TTM

ADMA Biologics Inc

15.910

-0.250-1.55%
Intraday
1m
30m
1h
D
W
M
D

Today

-1.55%

5 Days

-1.24%

1 Month

-8.77%

6 Months

-22.80%

Year to Date

-7.23%

1 Year

-19.40%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
24 / 175
Overall Ranking
104 / 4720
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 4 analysts
Buy
Current Rating
29.060
Target Price
+79.83%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 176.77% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD 197.67M.%!(EXTRA int=2)
Fairly Valued
The company’s latest PE is 17.91, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 225.21M shares, decreasing 2.66% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 21.31M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Ticker SymbolADMA
CompanyADMA Biologics Inc
CEOMr. Adam S. Grossman
Websitehttps://www.admabiologics.com/
KeyAI